KOD vs. FENC, IPSC, INMB, ELEV, OPT, IPHA, ADVM, GNFT, ABOS, and CMPX
Should you be buying Kodiak Sciences stock or one of its competitors? The main competitors of Kodiak Sciences include Fennec Pharmaceuticals (FENC), Century Therapeutics (IPSC), INmune Bio (INMB), Elevation Oncology (ELEV), Opthea (OPT), Innate Pharma (IPHA), Adverum Biotechnologies (ADVM), Genfit (GNFT), Acumen Pharmaceuticals (ABOS), and Compass Therapeutics (CMPX). These companies are all part of the "biological products, except diagnostic" industry.
Kodiak Sciences (NASDAQ:KOD) and Fennec Pharmaceuticals (NASDAQ:FENC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, community ranking, risk, institutional ownership and media sentiment.
Fennec Pharmaceuticals received 175 more outperform votes than Kodiak Sciences when rated by MarketBeat users. Likewise, 65.65% of users gave Fennec Pharmaceuticals an outperform vote while only 28.13% of users gave Kodiak Sciences an outperform vote.
Kodiak Sciences has a beta of 2.25, meaning that its stock price is 125% more volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500.
In the previous week, Fennec Pharmaceuticals had 13 more articles in the media than Kodiak Sciences. MarketBeat recorded 20 mentions for Fennec Pharmaceuticals and 7 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.73 beat Fennec Pharmaceuticals' score of 0.04 indicating that Kodiak Sciences is being referred to more favorably in the media.
89.1% of Kodiak Sciences shares are held by institutional investors. Comparatively, 55.5% of Fennec Pharmaceuticals shares are held by institutional investors. 45.3% of Kodiak Sciences shares are held by insiders. Comparatively, 11.3% of Fennec Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Fennec Pharmaceuticals has higher revenue and earnings than Kodiak Sciences. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.
Kodiak Sciences has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -75.50%. Fennec Pharmaceuticals' return on equity of 0.00% beat Kodiak Sciences' return on equity.
Kodiak Sciences presently has a consensus target price of $5.50, suggesting a potential upside of 47.06%. Fennec Pharmaceuticals has a consensus target price of $16.00, suggesting a potential upside of 124.72%. Given Fennec Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Fennec Pharmaceuticals is more favorable than Kodiak Sciences.
Summary
Fennec Pharmaceuticals beats Kodiak Sciences on 10 of the 17 factors compared between the two stocks.
Get Kodiak Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for KOD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KOD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kodiak Sciences Competitors List
Related Companies and Tools
